- Christophe Weber, Takeda President and Chief Executive Officer Highlights of Takeda's 2025 Annual Integrated Report Groundbreaking science ...

- Christophe Weber, Takeda President and Chief Executive Officer Highlights of Takeda’s 2025 Annual Integrated Report Groundbreaking science In FY2024, Takeda invested USD 4.9 billion in research and ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled stud ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential ...